A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Clinical trial NCT07377578 · RECRUITING
Trial details
- NCT number
- NCT07377578
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-05
- Primary completion
- 2031-05-30
- Enrollment
- 394
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.